
Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%
Bristol-Myers Squibb increased its full-year 2026 earnings guidance following a 12% revenue growth in its growth portfolio to $7.7 billion, driven by eight medicines each generating over $1 billion annually. The company is offsetting losses from pate...





